# Appendix 1. Checklist of PRISMA guideline

<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item #</th>
<th>Checklist Item</th>
<th>Location where item is reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review.</td>
<td>p. 1 Title</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract</td>
<td>2</td>
<td>See the PRISMA 2020 Abstracts checklist.</td>
<td>p. 3 abstract</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of existing knowledge.</td>
<td>p. 5-6 Background</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of the objective(s) or question(s) the review addresses.</td>
<td>p. 6 Objective</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>5</td>
<td>Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.</td>
<td>p. 7 Search strategy and inclusion criteria</td>
</tr>
<tr>
<td>Information sources</td>
<td>6</td>
<td>Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.</td>
<td>p. 7 Search strategy and inclusion criteria</td>
</tr>
<tr>
<td>Search strategy</td>
<td>7</td>
<td>Present the full search strategies for all databases, registers and websites, including any filters and limits used.</td>
<td>p. 7 Search strategy and inclusion criteria, Appendix 2</td>
</tr>
<tr>
<td>Selection process</td>
<td>8</td>
<td>Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.</td>
<td>p. 7 Search strategy and inclusion criteria</td>
</tr>
<tr>
<td>Data collection process</td>
<td>9</td>
<td>Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>Data items</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10a</td>
<td></td>
<td>List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>10b</td>
<td></td>
<td>List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>Study risk of bias assessment</td>
<td>11</td>
<td>Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>Effect measures</td>
<td>12</td>
<td>Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>Synthesis methods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13a</td>
<td></td>
<td>Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).</td>
<td>p. 8-9 Data analysis</td>
</tr>
<tr>
<td>13b</td>
<td></td>
<td>Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.</td>
<td>p. 8 Outcome measures and target population</td>
</tr>
<tr>
<td>13c</td>
<td></td>
<td>Describe any methods used to tabulate or visually display results of individual studies and syntheses.</td>
<td>p. 8-9 Data analysis</td>
</tr>
<tr>
<td>Section and Topic</td>
<td>Item #</td>
<td>Checklist Item</td>
<td>Location where item is reported</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Study selection</td>
<td>16a</td>
<td>Describe the results of the search and selection process, from the number of</td>
<td>p.10 2nd paragraph of Findings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>records identified in the search to the number of studies included in the review,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ideally using a flow diagram.</td>
<td></td>
</tr>
<tr>
<td>Study characteristics</td>
<td>17</td>
<td>Cite each included study and present its characteristics.</td>
<td>eTable 1</td>
</tr>
<tr>
<td>Risk of bias in studies</td>
<td>18</td>
<td>Present assessments of risk of bias for each included study.</td>
<td>eFigure 2, eFigure 3</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>19</td>
<td>For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.</td>
<td>p.10 2nd paragraph of Findings</td>
</tr>
<tr>
<td>Results of syntheses</td>
<td>20a</td>
<td>For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.</td>
<td>p.10 1st paragraph of Findings</td>
</tr>
<tr>
<td></td>
<td>20b</td>
<td>Present results of all statistical syntheses conducted. If meta-analysis was</td>
<td>p.10 2nd paragraph of Findings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20c</td>
<td>Present results of all investigations of possible causes of heterogeneity among</td>
<td>p.10 2nd paragraph of Findings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>study results.</td>
<td>eFigure 5</td>
</tr>
<tr>
<td>Reporting biases</td>
<td>21</td>
<td>Present assessments of risk of bias due to missing results (arising from</td>
<td>eFigure 2, eFigure 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>reporting biases) for each synthesis assessed.</td>
<td></td>
</tr>
<tr>
<td>Certainty of evidence</td>
<td>22</td>
<td>Present assessments of certainty (or confidence) in the body of evidence for each</td>
<td>eTable 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>outcome assessed.</td>
<td></td>
</tr>
</tbody>
</table>

**DISCUSSION**

<p>| Discussion | 23a   | Provide a general interpretation of the results in the context of other evidence. | p12 2nd paragraph of Discussion          |</p>
<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item #</th>
<th>Checklist Item</th>
<th>Location where item is reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>23b</td>
<td>Discuss any limitations of the evidence included in the review.</td>
<td>p14 Limitation</td>
<td></td>
</tr>
<tr>
<td>23c</td>
<td>Discuss any limitations of the review processes used.</td>
<td>p14 Limitation</td>
<td></td>
</tr>
<tr>
<td>23d</td>
<td>Discuss implications of the results for practice, policy, and future research.</td>
<td>p15 Clinical implications</td>
<td></td>
</tr>
</tbody>
</table>

**OTHER INFORMATION**

<table>
<thead>
<tr>
<th>Registration and protocol</th>
<th>24a</th>
<th>Provide registration information for the review, including register name and registration number, or state that the review was not registered.</th>
<th>Open Science Framework (DOI: 10.17605/OSF.IO/CYPV6)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24b</td>
<td>Indicate where the review protocol can be accessed, or state that a protocol was not prepared.</td>
<td>Open Science Framework (DOI: 10.17605/OSF.IO/CYPV6)</td>
</tr>
<tr>
<td></td>
<td>24c</td>
<td>Describe and explain any amendments to information provided at registration or in the protocol.</td>
<td>None</td>
</tr>
<tr>
<td>Support</td>
<td>25</td>
<td>Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.</td>
<td>None</td>
</tr>
<tr>
<td>Competing interests</td>
<td>26</td>
<td>Declare any competing interests of review authors.</td>
<td>None</td>
</tr>
<tr>
<td>Availability of data, code and other materials</td>
<td>27</td>
<td>Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.</td>
<td>Supplementary and appendix</td>
</tr>
</tbody>
</table>
### Appendix 2.

**Database**

**MEDLINE search strategy**

<table>
<thead>
<tr>
<th>Search Term</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;bipolar and related disorders&quot;/.mp. or &quot;bipolar and related disorders&quot;.mp.</td>
<td>54249</td>
</tr>
<tr>
<td>mania or manic.mp.</td>
<td>19561</td>
</tr>
<tr>
<td>affective psychosis.mp.</td>
<td>1014</td>
</tr>
<tr>
<td>rapid cycling.mp.</td>
<td>1360</td>
</tr>
<tr>
<td>(psychos* or psychotic or anti-psycho* or antipsycho*).ti,kf.</td>
<td>107641</td>
</tr>
<tr>
<td>or/1-5</td>
<td>159894</td>
</tr>
<tr>
<td>Amisulpride/ or Amisulpride.mp.</td>
<td>1393</td>
</tr>
<tr>
<td>Blonanserin.mp.</td>
<td>178</td>
</tr>
<tr>
<td>Risperidone/ or Risperidone.mp.</td>
<td>10808</td>
</tr>
<tr>
<td>Quetiapine Fumarate/ or Quetiapine Fumarate.mp.</td>
<td>3103</td>
</tr>
<tr>
<td>Paliperidone Palmitate/ or Paliperidone Palmitate.mp. or Paliperidone.mp.</td>
<td>1643</td>
</tr>
<tr>
<td>Lumateperone.mp.</td>
<td>45</td>
</tr>
<tr>
<td>Olanzapine/ or Olanzapine.mp.</td>
<td>10059</td>
</tr>
<tr>
<td>Lurasidone Hydrochloride/ or Lurasidone Hydrochloride.mp.</td>
<td>332</td>
</tr>
<tr>
<td>Haloperidol/ or Haloperidol.mp.</td>
<td>22927</td>
</tr>
<tr>
<td>cariprazine.mp.</td>
<td>330</td>
</tr>
<tr>
<td>Perospirone.mp.</td>
<td>161</td>
</tr>
<tr>
<td>asenapine.mp.</td>
<td>467</td>
</tr>
<tr>
<td>Aripiprazole/ or Aripiprazole.mp.</td>
<td>4815</td>
</tr>
<tr>
<td>Clozapine/ or Clozapine.mp.</td>
<td>13884</td>
</tr>
<tr>
<td>Brexpiprazole.mp.</td>
<td>282</td>
</tr>
<tr>
<td>Iloperidone.mp.</td>
<td>224</td>
</tr>
<tr>
<td>Melperone.mp.</td>
<td>154</td>
</tr>
<tr>
<td>Pimavanserin.mp.</td>
<td>263</td>
</tr>
<tr>
<td>Remoxipride/ or Remoxipride.mp.</td>
<td>380</td>
</tr>
<tr>
<td>Ziprasidone.mp.</td>
<td>2091</td>
</tr>
<tr>
<td>Antipsychotic Agents/ or Antipsychotic Agents.mp.</td>
<td>58790</td>
</tr>
<tr>
<td>or/7-27</td>
<td>85330</td>
</tr>
<tr>
<td>6 and 28</td>
<td>25437</td>
</tr>
<tr>
<td>randomized controlled trial.pt.</td>
<td>576271</td>
</tr>
<tr>
<td>randomi*.ti,ab,kf.</td>
<td>750128</td>
</tr>
<tr>
<td>(RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,kf.</td>
<td>263507</td>
</tr>
<tr>
<td>trial.ti.</td>
<td>265008</td>
</tr>
<tr>
<td>clinical trials as topic.sh.</td>
<td>200326</td>
</tr>
<tr>
<td>placebo.ti,ab,kf.</td>
<td>235339</td>
</tr>
<tr>
<td>((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).ti,ab,kf.</td>
<td></td>
</tr>
</tbody>
</table>
Cochrane Central Register of Controlled Trials (CENTRAL) search strategy

#1 MeSH descriptor: [Bipolar Disorder] explode all trees (2890)
#2 (bipolar disorder):ti,ab,kw(7150)
#3 MeSH descriptor: [Bipolar and Related Disorders] explode all trees(2891)
#4 (bipolar and related disorders):ti,ab,kw(1658)
#5 MeSH descriptor: [Mania] explode all trees (21)
#6 (mania or manic):ti,ab,kw(3429)
#7 (affective psychosis):ti,ab,kw(927)
#8 (rapid cycling):ti,ab,kw(1921)
#9 #1 or #2 or #3 or #4 or #6 or #7 or #8(10562)
#10 MeSH descriptor: [Risperidone] explode all trees (1443)
#11 (Risperidone):ti,ab,kw(3658)
#12 MeSH descriptor: [QuetiapineFumarate] explode all trees (749)
#13 (Quetiapine):ti,ab,kw(1998)
#14 MeSH descriptor: [Paliperidone Palmitate] explode all trees(252)
#15 (Paliperidone):ti,ab,kw(655)
#16 MeSH descriptor: [Amisulpride] explode all trees (149)
#17 (Amisulpride):ti,ab,kw(512)
#18 MeSH descriptor: [Olanzapine] explode all trees(1354)
#19 (Olanzapine):ti,ab,kw(3698)
#20 MeSH descriptor: [Haloperidol] explode all trees (1425)
#21 (Haloperidol):ti,ab,kw(3266)
#22 (cariprazine):ti,ab,kw(188)
#23 (asenapine):ti,ab,kw(194)
#24 MeSH descriptor: [Aripiprazole] explode all trees (626)
#25 (Aripiprazole):ti,ab,kw(1704)
#26 MeSH descriptor: [Clozapine] explode all trees(527)
#27 (Clozapine):ti,ab,kw(1559)
#28 (Blonanserin):ti,ab,kw(67)
#29 (Brexpiprazole):ti,ab,kw (174)
#30 (Iloperidone):ti,ab,kw(71)
#31 (Lumateperone):ti,ab,kw(50)
#32 MeSH descriptor: [Lurasidone Hydrochloride] explode all trees(119)
#33 (Lurasidone):ti,ab,kw(504)
#34 (Melperone):ti,ab,kw(36)
#35 (Perospirone):ti,ab,kw(38)
#36 (Pimavanserin):ti,ab,kw(113)
#37 MeSH descriptor: [Remoxipride] explode all trees(55)
#38 (Remoxipride):ti,ab,kw(86)
#39 (Ziprasidone):ti,ab,kw(780)
#40 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39(12624)
#41 #9 and #40(2002)
#42 (randomized controlled trial):ti,ab,kw(736915)
#43 #41 and #42(890)

**Embase search strategy**

1. 'bipolar disorder'/exp OR 'bipolar disorder' (85,016)
2. 'bipolar and related disorders'/exp OR 'bipolar and related disorders' (79,962)
3. 'mania'/exp OR mania (93,293)
4. 'affective psychosis'/exp OR 'affective psychosis' (2,814)
5. 'rapid cycling' (2,087)
6. 'psychotic'/exp OR psychotic (331,035)
7. 'risperidone'/exp OR risperidone (39,343)
8. 'quetiapine'/exp OR quetiapine (25,746)
9. 'paliperidone'/exp OR paliperidone (5,208)
10. 'amisulpride'/exp OR amisulpride(6,125)
11. 'olanzapine'/exp OR olanzapine (36,912)
12. 'haloperidol'/exp OR haloperidol (62,652)
13. 'cariprazine'/exp OR cariprazine (732)
14. 'asenapine'/exp OR asenapine (1,659)
15. 'aripiprazole'/exp OR aripiprazole (17,284)
16. 'clozapine'/exp OR clozapine (35,875)
17. 'blonanserin'/exp OR blonanserin(470)
18. 'brexpiprazole'/exp OR brexpiprazole (628)
19. 'iloperidone'/exp OR iloperidone (895)
20. 'lumateperone'/exp OR lumateperone(129)
21. 'lurasidone'/exp OR lurasidone (1,982)
22. 'melperone'/exp OR melperone(952)
23. 'perospirone'/exp OR perospirone(510)
24. 'pimavanserin'/exp OR pimavanserin(644)
25. 'remoxipride'/exp OR remoxipride(1,037)
26. 'ziprasidone'/exp OR ziprasidone (9,535)
27. #1 OR #2 OR #3 OR #4 OR #5 OR #6 (392,373)
28. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 (134,246)
29. #27 AND #28 (134,246)
30. #29 AND 'randomized controlled trial'/de (3,987)
<table>
<thead>
<tr>
<th>PsycINFO search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1 bipolar disorder OR (bipolar and related disorders) (44,887)</td>
</tr>
<tr>
<td>S2 mania OR manic (25,051)</td>
</tr>
<tr>
<td>S3 affective psychosis (1,906)</td>
</tr>
<tr>
<td>S4 rapid cycling (1,096)</td>
</tr>
<tr>
<td>S5 psychotic (107,242)</td>
</tr>
<tr>
<td>S6 S1 OR S2 OR S3 OR S4 OR S5 (150,936)</td>
</tr>
<tr>
<td>S7 risperidone (7,854)</td>
</tr>
<tr>
<td>S8 quetiapine or seroquel (4,104)</td>
</tr>
<tr>
<td>S9 paliperidone (879)</td>
</tr>
<tr>
<td>S10 Amisulpride (848)</td>
</tr>
<tr>
<td>S11 Olanzapine (6,762)</td>
</tr>
<tr>
<td>S12 haloperidol (10,033)</td>
</tr>
<tr>
<td>S13 cariprazine (152)</td>
</tr>
<tr>
<td>S14 asenapine (251)</td>
</tr>
<tr>
<td>S15 aripiprazole (3,212)</td>
</tr>
<tr>
<td>S16 clozapine (8,849)</td>
</tr>
<tr>
<td>S17 Blonanserin (102)</td>
</tr>
<tr>
<td>S18 brexpiprazole (132)</td>
</tr>
<tr>
<td>S19 iloperidone (106)</td>
</tr>
<tr>
<td>S20 lumateperone (13)</td>
</tr>
<tr>
<td>S21 lurasidone (297)</td>
</tr>
<tr>
<td>S22 Melperone (66)</td>
</tr>
<tr>
<td>S23 Perospirone (101)</td>
</tr>
<tr>
<td>S24 Pimavanserin (81)</td>
</tr>
<tr>
<td>S25 Remoxipride (178)</td>
</tr>
<tr>
<td>S26 ziprasidone (1,388)</td>
</tr>
<tr>
<td>S27 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 (29,614)</td>
</tr>
<tr>
<td>S28 S6 and S27 (10,526)</td>
</tr>
<tr>
<td>S29 S28 AND randomized controlled trial (1,025)</td>
</tr>
</tbody>
</table>

ClinicalTrials.gov (https://clinicaltrials.gov/)

Olanzapine | Bipolar Disorder, Manic (26)
Risperdal | Bipolar Disorder, Manic (6)
Quetiapine | Bipolar Disorder, Manic (29)
Paliperidone | Bipolar Disorder, Manic (5)
Amisulpride | Bipolar Disorder, Manic (1)
Haloperidol | Bipolar Disorder, Manic (6)
Cariprazine | Bipolar Disorder, Manic (3)
Asenapine | Bipolar Disorder, Manic (11)
Aripiprazole | Bipolar Disorder, Manic (18)
Clozapine | Bipolar Disorder, Manic (1)
Blonanserin | Bipolar Disorder, Manic (0)
Iloperidone | Bipolar Disorder, Manic (0)
Lumateperone | Bipolar Disorder, Manic (0)
Lurasidone | Bipolar Disorder, Manic (1)
Melperone | Bipolar Disorder, Manic (0)
Perospirone | Bipolar Disorder, Manic (0)
Pimavanserin | Bipolar Disorder, Manic (0)
Remoxipride | Bipolar Disorder, Manic (0)
Ziprasidone | Bipolar Disorder, Manic (15)

**World Health Organization (ICTRP)(https://trialsearch.who.int/AdvSearch.aspx)**

(Bipolar Disorder or Mania) AND Risperidone (8)
(Bipolar Disorder or Mania) AND Quetiapine (23)
(Bipolar Disorder or Mania) AND Paliperidone (3)
(Bipolar Disorder or Mania) AND Olanzapine (13)
(Bipolar Disorder or Mania) AND Haloperidol (1)
(Bipolar Disorder or Mania) AND Cariprazine (5)
(Bipolar Disorder or Mania) AND Asenapine (8)
(Bipolar Disorder or Mania) AND Aripiprazole (21)
(Bipolar Disorder or Mania) AND Clozapine (0)
(Bipolar Disorder or Mania) AND Blonanserin (0)
(Bipolar Disorder or Mania) AND Brexpiprazole (6)
(Bipolar Disorder or Mania) AND Iloperidone (1)
(Bipolar Disorder or Mania) AND Lumateperone (2)
(Bipolar Disorder or Mania) AND Lurasidone (5)
(Bipolar Disorder or Mania) AND Melperone (0)
(Bipolar Disorder or Mania) AND Perospirone (0)
(Bipolar Disorder or Mania) AND Pimavanserin (0)
(Bipolar Disorder or Mania) AND Remoxipride (0)
(Bipolar Disorder or Mania) AND Ziprasidone (15)

CENTRAL: Cochrane Central Register of Controlled Trials
**Conference abstract (n = 9)**


**Not double-blinded randomized clinical trials (n=12)**


No outcome of interest (n=116)


49. Marcus R. Aripiprazole improved time to any mood episode when added to mood stabilizer. Psychiatric Annals. 2011;41(7):353-.


56. Missio G, Moreno DH, Fernandes F, Bio DS, Soeiro-de-Souza MG, Rodrigues dos Santos D, Jr., et al. The ARIQUELI study: potentiation of quetiapine in


86. Thompson MJ. 'Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar 1 disorder (trial 144: A randomized controlled study': Correction. The Journal of Clinical Psychiatry. 2014;75(3):290-.


112. Talaei A, Dastgheib MS, Soltanifar A, Mokhber N, Akhondzadeh S, Afzaljavan F. Oxcarbazepine versus sodium valproate in treatment of acute mania: A


**Duplicated database (n=27)**


24. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two


Fixed dose or no dose reported (n=13)


Not superior to placebo (n=1)

Unpublished clinical trials, which did not meet our inclusion criteria (n=12)


4. Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunctto Lithium in the Treatment of Patients with Acute Mania in Bipolar Disorder. https://clinicaltrials.gov/show/NCT00672490 => no dose reported

5. Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults with Acute Mania or Mixed Episodes. https://clinicaltrials.gov/show/NCT00397020 => no dose reported


7. Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder. https://clinicaltrials.gov/show/NCT01195363 => no dose reported

8. Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786). https://clinicaltrials.gov/show/NCT00145509 => no outcome of interest

9. Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder. https://clinicaltrials.gov/show/NCT00665366 => no outcome of interest
10. A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode. https://clinicaltrials.gov/show/NCT00606320 => no outcome of interest


12. 3-week Study to Evaluate Efficacy and Safety of Ziprasidone with Either Lithium or Divalproex in Acutely Manic Subjects. https://clinicaltrials.gov/show/NCT00312494 => no outcome of interest
Appendix 3. Formula of Efficacy-adjusted weighted mean dose method for antipsychotic dose equivalence

Formula

\[ \log\left(\frac{\text{WMD}_A}{\text{WMD}_B}\right) \times W = \text{SMD}_{\text{Drug A-Drug B}} \]

\[ \text{Eq} = \frac{1}{W} \]

\text{WMD}_A : \text{weighted mean dose of drug A}
\text{WMD}_B : \text{weighted mean dose of drug B}
\text{SMD}_{\text{Drug A-Drug B}}: \text{the difference of drug A versus drug (positive value indicates that A is superior to B)}
\text{W}: \text{coefficient}
\text{Eq}: \text{the dose equivalence of drug A to drug B}

Example: Haloperidol equivalent to 1 mg olanzapine (without significantly different efficacy)

\[ \log\left(\frac{10.15}{14.89}\right) \times W = 0 \] (because these two drug did not significantly differ in SMD, we set this value as zero)

\[ \text{Eq} = \frac{1}{W} = 0.68 \] (0.68 mg of haloperidol is equivalent to 1 mg of olanzapine)

Example: Risperidone equivalent to 1 mg olanzapine (without efficacy-adjusted)

\[ \log\left(\frac{4.72}{14.89}\right) \times W = 0 \] (without efficacy-adjusted)

\[ \text{Eq} = 0.32 \]

\[ \log\left(\frac{4.72}{14.89}\right) \times W = 0.22 \] (with efficacy-adjusted; see League table (Figure 1))

\[ \text{Eq} = 0.19 \]